StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their target price on Trevena from $9.00 to $5.00 and set a buy rating on the stock in a report on Thursday, May 16th.
Check Out Our Latest Research Report on TRVN
Trevena Stock Up 5.3 %
Trevena (NASDAQ:TRVN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. The company had revenue of $0.02 million during the quarter. On average, sell-side analysts expect that Trevena will post -1.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Trevena
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent quarter. 13.56% of the stock is currently owned by institutional investors and hedge funds.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- How to Effectively Use the MarketBeat Ratings Screener
- Survey: Top 175 Fittest Retirement Locations in America
- The How and Why of Investing in Gold Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is Forex and How Does it Work?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.